Developer docs
API playgroundTry for free, no card

Search company profiles

HitGen

Full company profile

uuid0003u24

Namestring
HitGen
Legal namestring
HitGen Inc.
Websiteurl
hitgen.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

HitGen Inc. (SSE: 688222.SH) is a Chengdu-headquartered, publicly listed biopharmaceutical company founded in 2012 that provides early-stage drug discovery services and technologies to pharmaceutical, biotechnology, chemical, foundation, and academic clients globally. Its core platform is a proprietary DNA-encoded Library (DEL) containing over 1.2 trillion compounds, built using split-and-pool synthesis, validated on-DNA chemistry (100+ reaction protocols, 30,000+ building blocks), and NGS-driven selection workflows; HitGen has expressed 110+ target proteins and solved over 6,000 drug/target crystal structures through its X-ray crystallography and synchrotron access (SSRF, Spring-8). The company has extended this DEL center of gravity into Fragment-Based Drug Discovery and Structure-Based Drug Design via its wholly-owned Vernalis (R&D) Limited subsidiary in Cambridge UK (acquired October 2020 for $25M), and into Protein Degradation (PROTAC and molecular glues), Oligonucleotide Therapeutics (siRNA, CDMO), and Cyclic Peptomimetics, supported by biophysics platforms (Biacore, Octet, ITC, TSA, TRIC) and in-house computational capabilities.

The proprietary HAILO platform combines DEL screening with AI-based scaffold hopping, ADMET prediction, and automated synthesis, co-developed with a major Internet company. HitGen monetizes through a multi-model commercial approach: technical services billed under Fee For Service (FFS), Full-time Equivalent (FTE), or Integrated Drug Discovery Service (IDDS) multi-year contracts; technology licensing of its DEL IP (OpenDEL™, DEL EZ™); risk-sharing and collaborative ventures with milestone and royalty components; and tool/product sales. Operational reach spans Chengdu (HQ and 10,000+ sqm of lab space plus a new Global Drug R&D and Production Base Phase I completed December 2025), Cambridge UK (Vernalis), and Houston, USA. The company reports having served over 600 clients globally by end of 2025, advancing multiple internal preclinical and clinical programs in parallel with client work, and has formalized ESG positioning through an SBTi commitment (December 2025) and a published 2025 Sustainability Report.

Short descriptiontext

HitGen Inc. (SSE: 688222.SH) is a Chengdu-based, publicly listed biotech that provides early-stage drug discovery services and DEL technology to 600+ global pharma, biotech, chemical, foundation, and academic clients, with subsidiaries in Cambridge UK (Vernalis) and Houston USA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersChengdu, China
HQ citystring
Chengdu
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA-encoded library screening, drug discovery services, contract research organization, fragment-based drug design, biotech research reagents
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Technical Services (Fee For Service)
TypeProfessional Services
Description

HitGen provides comprehensive drug discovery services including target validation, hit identification, hit-to-lead, lead optimization, preclinical studies, IND filing and clinical development centered around DEL technologies and FBDD. Services are offered through flexible business models including single capability-based Fee For Service (FFS) and Full-time Equivalent (FTE) arrangements.

hitgen.com
2Project Out-licensing
TypeLicensing Royalties
Description

Risk-sharing projects and collaborative ventures where HitGen develops drug candidates and out-licenses them to pharmaceutical partners. The company also advances multiple internal programs at various clinical and preclinical stages.

hitgen.com
3DEL Platform Licensing
TypeLicensing Royalties
Description

Licensing of DEL technology, OpenDEL product, and DEL EZ toolkit to pharmaceutical and biotech companies for their own drug discovery programs.

hitgen.com
4Product Sales
TypeOne Time License
Description

Sale of tool molecules, validated siRNAs, nucleotides, and other research reagents to pharmaceutical and biotech customers.

hitgen.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Fee For Service (FFS) - Single capability-based service model
ModelOtherBilling cadenceMulti-year contract
Notes

Single capability-based service where clients pay for specific drug discovery services such as DEL screening, hit identification, or lead optimization.

hitgen.com
2Full-time Equivalent (FTE) - Dedicated team-based model
ModelOtherBilling cadenceMulti-year contract
Notes

Client resources dedicated HitGen scientists and teams for drug discovery projects.

hitgen.com
3Integrated Drug Discovery Service (IDDS)
ModelOtherBilling cadenceMulti-year contract
Notes

Comprehensive integrated service covering multiple stages of drug discovery from target validation to clinical development.

hitgen.com
4Risk-sharing and Collaborative Ventures
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Shared risk arrangements where HitGen participates in the success of drug development programs through milestone payments and royalties.

hitgen.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1OpenDEL
Description

DNA-encoded library product offering for hit identification

hitgen.com
+4 more records
Core offering1 text field

HitGen is a drug-discovery contract research organization that builds and applies proprietary DNA-encoded library (DEL) technology to discover small-molecule hits and leads for pharmaceutical and biotechnology clients. Its core offerings include the OpenDEL™ screening platform, the HAILO AI-driven molecular optimization platform, off-the-shelf DEL EZ™ screening kits, and supporting services such as DEL library synthesis, fragment-based drug design (FBDD), structure-based drug design (SBDD), and CDMO capabilities. The company sells these capabilities as fee-for-service and collaborative drug-discovery engagements to biopharma customers worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 600 clients globally empowered as of end of 2025
+3 more records
Product overview1 text field

HitGen is a biopharmaceutical company operating a diversified drug discovery platform centered on its internationally leading DNA-encoded Library (DEL) technology, which has synthesized over 1.2 trillion compounds. The company has expanded into complementary platforms including Fragment-Based Drug Discovery (FBDD) and Structure-Based Drug Design (SBDD) through its Vernalis subsidiary, Oligonucleotide-based Therapeutics, Targeted Proximity Drugs (PROTAC/Molecular Glue), and Cyclic Peptidomimetics. The proprietary HAILO platform integrates DEL+AI+Automation for molecular optimization. HitGen offers flexible business models including technical services, project out-licensing, and product sales through its integrated one-stop drug discovery platform spanning target validation to clinical development, with operations in Chengdu (headquarters), Cambridge UK, and Houston USA.

Product and service7 records
1OpenDEL™ DEL Screening Service
CategoryDrug Discovery Services
Description

HitGen's proprietary DNA-encoded library (DEL) screening service that screens very large chemical space in a single experiment against customer-supplied targets to identify small-molecule hit compounds. Offered to pharmaceutical, biotechnology, and chemical industry R&D teams as a fee-for-service or collaborative drug-discovery engagement.

2HAILO Molecular Optimization Platform
CategoryAI-enabled Drug Discovery Software / Services
Description

HitGen's proprietary AI-enabled platform used for molecular optimization, hit-to-lead progression, and data interpretation around DEL screening results. Sold primarily as part of collaborative drug-discovery engagements with biopharma customers.

3DEL EZ™ Off-the-Shelf Screening Kit
CategoryResearch Reagents / Screening Products
Description

Off-the-shelf, ready-to-use DNA-encoded library screening kit product that allows academic, biotech, and industrial chemistry customers to perform DEL screening without building in-house DEL capability. Sold as a discrete product to researchers and smaller organizations.

4DEL Synthesis Services
CategoryDEL Chemistry Services
Description

Custom synthesis of DNA-encoded libraries for clients who want to build or augment their own DEL collections. Offered to biopharma and research customers as a service engagement.

5Fragment-Based Drug Design (FBDD) Services
CategoryDrug Discovery Services
Description

Fragment-based drug design services providing fragment library screening and fragment-to-lead optimization for small-molecule drug discovery programs. Sold to pharmaceutical and biotech discovery teams.

6Structure-Based Drug Design (SBDD) Services
CategoryDrug Discovery Services
Description

Structure-based drug design services using structural biology and computational chemistry to support hit and lead optimization programs. Sold to pharmaceutical and biotech discovery teams.

7CDMO Services
CategoryPharmaceutical CDMO Services
Description

Contract development and manufacturing organization services for small-molecule chemical intermediates and drug substances, extending HitGen's offering beyond discovery into development for biopharma clients.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vernalis (R&D) Limited, headquartered in Cambridge, UK, is a wholly-owned subsidiary of HitGen. It integrates fragment-based approaches, protein science, structural biology, biophysics, assay technology and molecular modelling with extensive organic synthesis and medicinal chemistry expertise for drug discovery on both established and novel targets. This acquisition enhanced HitGen's FBDD capabilities with 20+ years of fragment-based lead discovery experience.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple collaborative projects with Pfizer including DEL selection for NAA50 inhibitors (published in ACS Med. Chem. Lett. 2020, 11, 1175-1184) and photoredox catalyzed [2+2] cyclization publication (Organic Letters 2020, 22, 2908-2913). The collaborations have yielded validated hits, including a potent Naa50 inhibitor with confirmed co-crystal structure.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Nuevolution (Amgen)
TypeDirect peer
Description

Pioneering DEL platform now owned by Amgen, representing a vertically-integrated competitor where DEL tech is captive rather than sold externally. Comparable at the technology layer and validates pharma demand for DEL.

TypeDirect peer
Description

German-listed drug discovery CRO/Contract Research Alliance offering FBDD/SBDD, medicinal chemistry, PROTAC discovery, and AI-driven platforms. Comparable in service breadth and target customer base; both operate internal pipelines alongside fee-for-service work.

TypeRegional player
Description

China-based small-molecule CDMO and oligonucleotide CDMO. Overlaps with HitGen's emerging oligonucleotide CDMO offering in target capabilities and customer base within the Asia-Pacific region.

TypeDirect peer
Description

Danish DEL technology specialist offering YoctoReactor DNA-encoded library screening and Binder Selection Enrichment (BSE) platforms. Directly comparable as a DEL-tech niche peer to a specific slice of HitGen's service offering.

TypeBroad incumbent
Description

Large US-headquartered CRO with broad discovery, safety, and manufacturing services spanning small and large molecules. Overlaps with HitGen in discovery services though broader and not specialized in DEL.

TypeDirect peer
Description

US-based leader in DNA-Encoded Library technology with hundreds of billions of compounds. Closest like-for-like competitor in DEL screening services and DEL platform licensing, directly comparable on technology stack and customer overlap.

TypeDirect peer
Description

China-based CRO with labs in US/UK offering drug discovery and development services including medicinal chemistry, DMPK, biology, and structural biology. Comparable in scale, business model (FFS/FTE), and global pharma customer base.

TypeDirect peer
Description

China-headquartered, full-service pharma CRO/CDMO offering discovery, development, and manufacturing services to global pharma and biotech. Direct competitor to HitGen in drug discovery services with overlapping customer base, multi-modality service portfolio, and global footprint.

TypeDirect peer
Description

Shanghai-headquartered CRO providing integrated drug discovery including medicinal chemistry, biology, DMPK, and structural biology for global pharma/biotech. Direct competitor in Asia-anchored discovery services with similar B2B sales motion.

TypeDirect peer
Description

UK-based integrated drug discovery CRO with strength in medicinal chemistry, FBDD/SBDD, and biology. Highly comparable to HitGen's Vernalis subsidiary offering; competes for European pharma discovery mandates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature14 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HitGen

Drug Discovery Serviceshitgen.com

HitGen Inc. (SSE: 688222.SH) is a Chengdu-based, publicly listed biotech that provides early-stage drug discovery services and DEL technology to 600+ global pharma, biotech, chemical, foundation, and academic clients, with subsidiaries in Cambridge UK (Vernalis) and Houston USA.

What HitGen does

HitGen Inc. (SSE: 688222.SH) is a Chengdu-headquartered, publicly listed biopharmaceutical company founded in 2012 that provides early-stage drug discovery services and technologies to pharmaceutical, biotechnology, chemical, foundation, and academic clients globally. Its core platform is a proprietary DNA-encoded Library (DEL) containing over 1.2 trillion compounds, built using split-and-pool synthesis, validated on-DNA chemistry (100+ reaction protocols, 30,000+ building blocks), and NGS-driven selection workflows; HitGen has expressed 110+ target proteins and solved over 6,000 drug/target crystal structures through its X-ray crystallography and synchrotron access (SSRF, Spring-8). The company has extended this DEL center of gravity into Fragment-Based Drug Discovery and Structure-Based Drug Design via its wholly-owned Vernalis (R&D) Limited subsidiary in Cambridge UK (acquired October 2020 for $25M), and into Protein Degradation (PROTAC and molecular glues), Oligonucleotide Therapeutics (siRNA, CDMO), and Cyclic Peptomimetics, supported by biophysics platforms (Biacore, Octet, ITC, TSA, TRIC) and in-house computational capabilities.

The proprietary HAILO platform combines DEL screening with AI-based scaffold hopping, ADMET prediction, and automated synthesis, co-developed with a major Internet company. HitGen monetizes through a multi-model commercial approach: technical services billed under Fee For Service (FFS), Full-time Equivalent (FTE), or Integrated Drug Discovery Service (IDDS) multi-year contracts; technology licensing of its DEL IP (OpenDEL™, DEL EZ™); risk-sharing and collaborative ventures with milestone and royalty components; and tool/product sales. Operational reach spans Chengdu (HQ and 10,000+ sqm of lab space plus a new Global Drug R&D and Production Base Phase I completed December 2025), Cambridge UK (Vernalis), and Houston, USA. The company reports having served over 600 clients globally by end of 2025, advancing multiple internal preclinical and clinical programs in parallel with client work, and has formalized ESG positioning through an SBTi commitment (December 2025) and a published 2025 Sustainability Report.

HitGen firmographics

Firmographics
Name
HitGen
Legal name
HitGen Inc.
Website
https://hitgen.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
HitGen Inc. (SSE: 688222.SH) is a Chengdu-based, publicly listed biotech that provides early-stage drug discovery services and DEL technology to 600+ global pharma, biotech, chemical, foundation, and academic clients, with subsidiaries in Cambridge UK (Vernalis) and Houston USA.
Ownership category
akta.pro rank

HitGen industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • DNA-encoded library screening
  • Drug discovery services
  • Contract research organization
  • Fragment-based drug design
  • Biotech research reagents

Where HitGen is headquartered

Location

Headquarters

HQ city
Chengdu
HQ country
China
HQ region
Asia

Offices4 records

Markets served

HitGen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Technical Services (Fee For Service): HitGen provides comprehensive drug discovery services including target validation, hit identification, hit-to-lead, lead optimization, preclinical studies, IND filing and clinical development centered around DEL technologies and FBDD. Services are offered through flexible business models including single capability-based Fee For Service (FFS) and Full-time Equivalent (FTE) arrangements.
  2. Project Out-licensing: Risk-sharing projects and collaborative ventures where HitGen develops drug candidates and out-licenses them to pharmaceutical partners. The company also advances multiple internal programs at various clinical and preclinical stages.
  3. DEL Platform Licensing: Licensing of DEL technology, OpenDEL product, and DEL EZ toolkit to pharmaceutical and biotech companies for their own drug discovery programs.
  4. Product Sales: Sale of tool molecules, validated siRNAs, nucleotides, and other research reagents to pharmaceutical and biotech customers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFee For Service (FFS) - Single capability-based service model
OtherMulti-year contractFull-time Equivalent (FTE) - Dedicated team-based model
OtherMulti-year contractIntegrated Drug Discovery Service (IDDS)
Outcome Based/ PerformanceMulti-year contractRisk-sharing and Collaborative Ventures

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

HitGen product offering

Product offering

Core offering

HitGen is a drug-discovery contract research organization that builds and applies proprietary DNA-encoded library (DEL) technology to discover small-molecule hits and leads for pharmaceutical and biotechnology clients. Its core offerings include the OpenDEL™ screening platform, the HAILO AI-driven molecular optimization platform, off-the-shelf DEL EZ™ screening kits, and supporting services such as DEL library synthesis, fragment-based drug design (FBDD), structure-based drug design (SBDD), and CDMO capabilities. The company sells these capabilities as fee-for-service and collaborative drug-discovery engagements to biopharma customers worldwide.

Product overview

HitGen is a biopharmaceutical company operating a diversified drug discovery platform centered on its internationally leading DNA-encoded Library (DEL) technology, which has synthesized over 1.2 trillion compounds. The company has expanded into complementary platforms including Fragment-Based Drug Discovery (FBDD) and Structure-Based Drug Design (SBDD) through its Vernalis subsidiary, Oligonucleotide-based Therapeutics, Targeted Proximity Drugs (PROTAC/Molecular Glue), and Cyclic Peptidomimetics. The proprietary HAILO platform integrates DEL+AI+Automation for molecular optimization. HitGen offers flexible business models including technical services, project out-licensing, and product sales through its integrated one-stop drug discovery platform spanning target validation to clinical development, with operations in Chengdu (headquarters), Cambridge UK, and Houston USA.

Differentiator

Problem solved

Functional benefit

Brands

  • OpenDEL: DNA-encoded library product offering for hit identification
  • DELEZ
  • HAILO
  • Vernalis
  • OpenDEL

Products and services

  • OpenDEL™ DEL Screening Service HitGen's proprietary DNA-encoded library (DEL) screening service that screens very large chemical space in a single experiment against customer-supplied targets to identify small-molecule hit compounds. Offered to pharmaceutical, biotechnology, and chemical industry R&D teams as a fee-for-service or collaborative drug-discovery engagement.
  • HAILO Molecular Optimization Platform HitGen's proprietary AI-enabled platform used for molecular optimization, hit-to-lead progression, and data interpretation around DEL screening results. Sold primarily as part of collaborative drug-discovery engagements with biopharma customers.
  • DEL EZ™ Off-the-Shelf Screening Kit Off-the-shelf, ready-to-use DNA-encoded library screening kit product that allows academic, biotech, and industrial chemistry customers to perform DEL screening without building in-house DEL capability. Sold as a discrete product to researchers and smaller organizations.
  • DEL Synthesis Services Custom synthesis of DNA-encoded libraries for clients who want to build or augment their own DEL collections. Offered to biopharma and research customers as a service engagement.
  • Fragment-Based Drug Design (FBDD) Services Fragment-based drug design services providing fragment library screening and fragment-to-lead optimization for small-molecule drug discovery programs. Sold to pharmaceutical and biotech discovery teams.
  • Structure-Based Drug Design (SBDD) Services Structure-based drug design services using structural biology and computational chemistry to support hit and lead optimization programs. Sold to pharmaceutical and biotech discovery teams.
  • CDMO Services Contract development and manufacturing organization services for small-molecule chemical intermediates and drug substances, extending HitGen's offering beyond discovery into development for biopharma clients.

Quantifiable outcome

  • Over 600 clients globally empowered as of end of 2025
  • +3 more outcomes

Companies that use HitGen

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles2 records

HitGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature14 records

HitGen partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Vernalis (R&D) LimitedcoreStrategic or Co-development PartnerVernalis (R&D) Limited, headquartered in Cambridge, UK, is a wholly-owned subsidiary of HitGen. It integrates fragment-based approaches, protein science, structural biology, biophysics, assay technology and molecular modelling with extensive organic synthesis and medicinal chemistry expertise for drug discovery on both established and novel targets. This acquisition enhanced HitGen's FBDD capabilities with 20+ years of fragment-based lead discovery experience.
  • PfizercoreStrategic or Co-development PartnerMultiple collaborative projects with Pfizer including DEL selection for NAA50 inhibitors (published in ACS Med. Chem. Lett. 2020, 11, 1175-1184) and photoredox catalyzed [2+2] cyclization publication (Organic Letters 2020, 22, 2908-2913). The collaborations have yielded validated hits, including a potent Naa50 inhibitor with confirmed co-crystal structure.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

HitGen competitors and assessment

Company assessment

Direct peers

  • Nuevolution (Amgen): Pioneering DEL platform now owned by Amgen, representing a vertically-integrated competitor where DEL tech is captive rather than sold externally. Comparable at the technology layer and validates pharma demand for DEL.
  • Evotec: German-listed drug discovery CRO/Contract Research Alliance offering FBDD/SBDD, medicinal chemistry, PROTAC discovery, and AI-driven platforms. Comparable in service breadth and target customer base; both operate internal pipelines alongside fee-for-service work.
  • Vipergen: Danish DEL technology specialist offering YoctoReactor DNA-encoded library screening and Binder Selection Enrichment (BSE) platforms. Directly comparable as a DEL-tech niche peer to a specific slice of HitGen's service offering.
  • X-Chem Pharmaceuticals: US-based leader in DNA-Encoded Library technology with hundreds of billions of compounds. Closest like-for-like competitor in DEL screening services and DEL platform licensing, directly comparable on technology stack and customer overlap.
  • Pharmaron: China-based CRO with labs in US/UK offering drug discovery and development services including medicinal chemistry, DMPK, biology, and structural biology. Comparable in scale, business model (FFS/FTE), and global pharma customer base.
  • WuXi AppTec: China-headquartered, full-service pharma CRO/CDMO offering discovery, development, and manufacturing services to global pharma and biotech. Direct competitor to HitGen in drug discovery services with overlapping customer base, multi-modality service portfolio, and global footprint.
  • ChemPartner: Shanghai-headquartered CRO providing integrated drug discovery including medicinal chemistry, biology, DMPK, and structural biology for global pharma/biotech. Direct competitor in Asia-anchored discovery services with similar B2B sales motion.
  • Sygnature Discovery: UK-based integrated drug discovery CRO with strength in medicinal chemistry, FBDD/SBDD, and biology. Highly comparable to HitGen's Vernalis subsidiary offering; competes for European pharma discovery mandates.

Regional players

  • WuXi STA (WuXi AppTec subsidiary): China-based small-molecule CDMO and oligonucleotide CDMO. Overlaps with HitGen's emerging oligonucleotide CDMO offering in target capabilities and customer base within the Asia-Pacific region.

Broad incumbents

  • Charles River Laboratories: Large US-headquartered CRO with broad discovery, safety, and manufacturing services spanning small and large molecules. Overlaps with HitGen in discovery services though broader and not specialized in DEL.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

HitGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HitGen leadership team

Management profile

Number of profiles

Profiles2 records

HitGen subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

HitGen funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HitGen M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HitGen

What does HitGen do?

HitGen is a drug-discovery contract research organization that builds and applies proprietary DNA-encoded library (DEL) technology to discover small-molecule hits and leads for pharmaceutical and biotechnology clients. Its core offerings include the OpenDEL™ screening platform, the HAILO AI-driven molecular optimization platform, off-the-shelf DEL EZ™ screening kits, and supporting services such as DEL library synthesis, fragment-based drug design (FBDD), structure-based drug design (SBDD), and CDMO capabilities. The company sells these capabilities as fee-for-service and collaborative drug-discovery engagements to biopharma customers worldwide.

Is HitGen a public or private company?

HitGen is a public company. It is classified as public and is currently operating.

When was HitGen founded?

HitGen was founded in 2012. It employs 51 to 100 people.

Where is HitGen based?

HitGen is headquartered in Chengdu, China, in the Asia region.

How does HitGen make money?

Four revenue lines are on record. Technical Services (Fee For Service) is the primary driver. The others are project Out-licensing, DEL Platform Licensing and product Sales.

Who are HitGen's main competitors?

Direct peers on record are Nuevolution (Amgen), Evotec, Vipergen, X-Chem Pharmaceuticals, Pharmaron, WuXi AppTec, ChemPartner and Sygnature Discovery. WuXi STA (WuXi AppTec subsidiary) is listed as a regional player. Charles River Laboratories is listed as a broad incumbent.

Does HitGen have an API?

No public API is recorded for HitGen.

What industry is HitGen in?

HitGen's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyBioAge doses first patient in Phase 2 trial of new cardiovascular drugBioAge Labs has dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102, a once-daily oral NLRP3 inhibitor being developed for cardiovascular risk reduction, with topline data anticipated in the second half of 2026. The drug was developed from a hit identified via HitGen's DNA-encoded library (DEL) technology and Phase 1 results positioned it as a potential best-in-class inhibitor with significant hsCRP reductions. The trial will evaluate participants at elevated cardiovascular risk and is designed to inform dose selection for Phase 3.Investing.comHitGen partner BioAge begins phase 2 trial of BGE-102 By Investing.comHitGen Inc. announced that its partner BioAge Labs has dosed the first participant in a Phase 2 clinical trial of BGE-102, an oral small molecule NLRP3 inhibitor for cardiovascular risk reduction. The QUELL-CV trial is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating BGE-102 in participants at elevated cardiovascular risk, with topline data expected in the second half of 2026. BGE-102 was developed from a compound identified through HitGen's DNA-Encoded Library technology platform, and the collaboration between the companies began with hit molecule identification announced in April 2021.PR NewswireHitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk ReductionBioAge Labs has dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept clinical trial for BGE-102, an oral NLRP3 inhibitor targeting cardiovascular risk reduction, with topline data expected in the second half of 2026. The compound was identified using HitGen's DNA-Encoded Library technology platform and demonstrated profound hsCRP reductions in Phase 1 trials, positioning it as a potential best-in-class NLRP3 inhibitor. The Phase 2 trial is designed to inform optimal dose selection for Phase 3 and BGE-102's path forward in cardiovascular disease.PR NewswireHitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk ReductionHitGen and BioAge Labs dosed the first participant in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The trial is dose-ranging and designed to inform Phase 3 selection, with topline data expected in the second half of 2026.PR NewswireHitGen veröffentlicht Nachhaltigkeitsbericht 2025HitGen Inc. (SSE: 688222.SH), a Shanghai Stock Exchange-listed biopharmaceutical company headquartered in Chengdu, China, published its 2025 sustainability report on April 29, 2026. This is the company's second sustainability report, outlining its ESG (Environmental, Social, and Governance) principles, guidelines, and performance for 2025, with the stated goal of addressing stakeholder concerns and demonstrating commitment to integrating sustainable development into business strategy and operations.PR NewswireHitGen publie son rapport 2025 sur le développement durableHitGen Inc., a biopharmaceutical company listed on the Shanghai Stock Exchange (SSE: 688222.SH), published its second sustainability report on April 29, 2026, covering the company's ESG principles, policies, practices, and results for fiscal year 2025. The report addresses stakeholder concerns across environmental management, social responsibility, and corporate governance areas. The company stated its commitment to integrating sustainable development into its overall strategy and operations as part of its goal to become a world-class innovative biopharmaceutical enterprise.PR NewswireESG | HitGen Releases 2025 Sustainability ReportHitGen Inc., a Shanghai Stock Exchange-listed biopharmaceutical company headquartered in Chengdu, China, released its second 2025 Sustainability Report on April 29, 2026, detailing the company's environmental, social, and governance philosophies and performance metrics. The report, covering sustainable development practices across their global operations spanning subsidiaries in the UK and USA, includes CEO Dr. Jin Li's statements emphasizing the company's commitment to integrating sustainability into strategy, management, and operations. The release represents a routine corporate ESG disclosure without announcing material financial results, strategic shifts, or significant transactions.PR NewswireESG | HitGen Releases 2025 Sustainability ReportShanghai Stock Exchange-listed HitGen Inc. released its 2025 Sustainability Report on April 29, 2026, marking the company's second sustainability disclosure focused on environmental, social, and governance performance. The report outlines HitGen's governance systems, responsible value chain practices, employee and community initiatives, and environmental management strategies as part of its stated goal to become a world-class innovative biopharmaceutical enterprise. The company emphasized integrating sustainable development into its overall strategy, management systems, and day-to-day operations.PR Newswire APACHitGen Releases 2025 Sustainability Report - PR Newswire APACHitGen Inc. released its 2025 Sustainability Report on April 29, 2026, detailing its ESG practices and performance. The report, the company's second, covers governance, supply chain, employees, community, and environment, with CEO Dr. Jin Li emphasizing integration into strategy and operations.PR NewswireHitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)HitGen Inc., a Shanghai Stock Exchange-listed life sciences company, has submitted a commitment letter to the Science Based Targets initiative (SBTi), pledging to set near-term science-based emission reduction targets within two years. The company aims to cut greenhouse gas emissions across its value chain in alignment with the 1.5°C temperature goal of the Paris Agreement. The commitment represents a step in HitGen's ESG strategy and long-term sustainable development goals.